About

Member has chosen to not make this information public.

Groups

Member not yet following any Groups.

Posts (23)

2 days ago · Mayo Clinic launches Vancomycin clinical trial for Primary Sclerosing Cholangitis in Primary Sclerosing Cholangitis (PSC)

2019-01-14 PSC Clinical Trial

Mayo Clinic in Minnesota, Arizona and Florida is currently conducting a randomized placebo controlled clinical trial, examining the impact of oral vancomycin on markers of cholestasis among patients with PSC. The treatment period is approximately 18 months and requires about five clinic visits along with lab draws at home.

Please contact Mr. Mitch Clayton (study coordinator) at 507-284-2698 or clayton.mitchell@mayo.edu for additional details.

A link to the study on clinicaltrials.gov is provided below:

https://bit.ly/2RjImYP 

Dec 16, 2019 · Statin Use and PSC in Primary Sclerosing Cholangitis (PSC)

2019-01-21 Statins PSC
In a recent paper published in the journal Clinical Gastroenterology and Hepatology,  Stokkeland K. et al., reported the effects of exposure to medications on the outcomes of PSC using a population-based cohort of 2,914 patients from Sweden. The authors found that use of statins or azathioprine, among patients with PSC, was associated with reduced risk of all cause mortality, death or liver transplantation. Of note, exposure to ursodeoxycholic acid did not affect the mortality of these patients. Despite the retrospective nature of this study, these interesting findings suggest pursuing further investigation on the role of statins in the outcomes of PSC.

Dec 2, 2019 · Coping Needs of Children with Primary Sclerosing Cholangitis in Primary Sclerosing Cholangitis (PSC)

2019-01-14 PSC Child

Primary Sclerosing Cholangitis (PSC) is a slowly progressing disease that affects both adults and children. Several of the clinical features of the disease are different between pediatric and adult patients. Importantly, the coping elements of the disease in children and their families are unique.

In this presentation, Dr. Mounif El-Youssef, an Associate Professor of Medicine and a Pediatric Hepatologist from Mayo Clinic, discusses the coping needs of a child diagnosed with PSC.

View the full presentation from Dr. El-Youssef.

Nov 18, 2019 · An Overview of Primary Sclerosing Cholangitis in Primary Sclerosing Cholangitis (PSC)

2019-01-16 PSC Liver

Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease that affects about 1 in 10,000 people.

In this presentation, Robert C. Huebert, M.D, an Associate Professor of Medicine and transplant Hepatologist from Mayo Clinic, provides a great overview of PSC, including promising approaches of regenerative medicine to treat the disease.

View the full presentation from Dr. Huebert.

Nov 4, 2019 · Bile Acid Profiles in Primary Sclerosing Cholangitis Predict Advancement of Disease in Primary Sclerosing Cholangitis (PSC)

2019-11-19 Artificial Intelligience

Meaningful and reliable predictors of disease progression in PSC are currently lacking despite efforts over the past three decades. Patients with PSC often demonstrate increased plasma bile acids (BA) concentrations due to ongoing cholestasis, a hallmark of the disease. However, the relationship between composition of the BA in blood and future development of advanced liver disease among patients with PSC remains unclear. In fact, an assessment of plasma BA as predictors of clinical progression in PSC has not been demonstrated. In our present study presented by Omar Mouse MD, et al., at the 2019 Annual conference of the American Associations for the Study of Liver Diseases (AASLD) we use machine learning, an artificial intelligence application, to establish a non-invasive, reliable BA-based model, that is predictive of events of liver disease advancement. More than 400 PSC patients participated from across the US and 108 patients with PSC from Norway were included to make this study possible. Our BA-based model could be useful in PSC prognostication and stratification into clinical trials.

Read the full abstracts from the PSC team

Oct 21, 2019 · Understanding the Mechanism of Aging Cholangiocytes in PSC in Primary Sclerosing Cholangitis (PSC)

PSC1021

Aging (senescent) bile duct cells , i.e., cholangiocytes, demonstrate an arrest of the cell cycle, hypersecretion of inflammatory molecules and resistance to cell death. O’Hara et al., previously reported that aging of cholangiocytes is a feature in PSC patients, and that this event is regulated by a central molecular pathway (Ras signaling) as well as the transcription factor, ETS1. In a recently published manuscript, his team further explored the molecular mechanisms regulating senescent cholangiocyte resistance to cell death. Using PSC patients derived tissues and an inducible cell culture model of cholangiocyte senescence, O’Hara et al., reported that the transcription factor, ETS1, interacts with a chromatin modifying enzyme, called p300, to induce the expression of a pro-survival protein, BCL-xL, which in turn promotes senescent cholangiocyte resistance to cell death. These new exciting data suggest that ETS1 is a central regulator of the senescent cholangiocyte phenotype. This novel knowledge provides the basis for exploring new targets for the therapeutic removal of aging cholangiocyte as an approach to treat PSC.

Read the full abstract from the PSC team.

Sep 23, 2019 · Biochemical and Imaging Biomarkers in PSC in Primary Sclerosing Cholangitis (PSC)

biomarker test

Primary Sclerosing Cholangitis (PSC) is a slowly progressing liver disease that lacks an ideal biomarker, which could predict disease progression. A biomarker is a measurable indicator of the presence or severity of a disease state. For example, body temperature is a biomarker of fever.

In this presentation, Dr. John Eaton, an Assistant Professor of Medicine and transplant Hepatologist from Mayo Clinic, discusses in detail the importance, current biomarkers of, and ongoing approaches to develop novel biomarkers for PSC.

View the full presentation from Dr. Eaton.

Sep 9, 2019 · Mayo Clinic PSC Abstracts Accepted for the 2019 Annual AASLD meeting in Primary Sclerosing Cholangitis (PSC)

AASLD Doctor with Stethoscope image

The American Association for the Study of Liver Disease (AASLD) is the leading society of scientists and health care professionals in the United States committed to preventing, diagnosing, and treating liver disease. During the annual AASLD meeting that will take place in Boston, MA (November 8-12, 2019) our group has submitted five scientific abstracts, which have being accepted for presentation. Accepted abstracts represent high caliber work, which will be shared with other scientists and health care professionals. Our work that was accepted for this meeting ranges from discovery, to translation, and to clinical application. We are very excited to share with our followers this work on PSC.

Abstract 1: Changes in Liver Stiffness Measured by Magnetic Resonance Elastography are Associated with Outcomes in Primary Sclerosing Cholangitis

Presenter: John E. Eaton, M.D.

Presentation Type: Poster Presentation
Presentation Date(s)/Time(s):

Friday, November 8: 8:00 am – 5:30 pm; Presenters Available: 12:30 – 1:30pm
Saturday, November 9: 2:00 pm–7:00 pm; Presenters Available: 5:15 – 6:15pm
Sunday, November 10: 8:00 am – 5:30 pm; Presenters Available: 12:30 – 1:30pm
Monday, November 11: 8:00 am – 5:30 pm; Presenters Available: 12:30 – 1:30pm

Location: Hynes Convention Center, Hall B

Financial Support: Chris M. Carlos and Catharine Nicole Jockisch Carlos Endowment Fund in Primary Sclerosing Cholangitis

 

Abstract 2: Therapeutic Targeting of Ductular Reactive Cells in Cholestatic Liver Disease

Presenter: Adiba I. Azad, M.D.

Presentation Type: Oral Presentation
Presentation Date/Time: Monday, November 11th at 5 p.m.

Location: Room 210, Hynes Convention Center

Financial Support: Chris M. Carlos and Catharine Nicole Jockisch Carlos Endowment Fund in Primary Sclerosing Cholangitis

 

Abstract 3: Modulation of the Intestinal Microbiome Alters Disease Progression in Germ Free Rodent Models of Primary Sclerosing Cholangitis

Presenter: Steven P. O’Hara, Ph.D.

Presentation Type: Poster Presentation

Presentation Date(s)/Time(s):

Friday, November 8: 8:00 am – 5:30 pm; Presenters Available: 12:30 – 1:30pm
Saturday, November 9: 2:00 pm–7:00 pm; Presenters Available: 5:15 – 6:15pm
Sunday, November 10: 8:00 am – 5:30 pm; Presenters Available: 12:30 – 1:30pm
Monday, November 11: 8:00 am – 5:30 pm; Presenters Available: 12:30 – 1:30pm

Location: Hynes Convention Center, Hall B

Financial Support: DK57993, DK84567, Chris M. Carlos and Catharine Nicole Jockisch Carlos Endowment Fund in Primary Sclerosing Cholangitis

 

Abstract 4: Bile Acid Profiles Predict Hepatic Decompensation in Primary Sclerosing Cholangitis

Presenter: Omar Y. Mousa, M.B.B.S.

Presentation Type: Oral Presentation
Presentation Date/Time: Monday, November 11th at 10:45 a.m.

Location: Constitution Ballroom, Hynes Convention Center

Financial Support: DK118619, Chris M. Carlos and Catharine Nicole Jockisch Carlos Endowment Fund in Primary Sclerosing Cholangitis, and PSC Partners Seeking A Cure

 

Abstract 5: Transcription Factor, ETS1, Interacts with Histone Acetyl Transferase, p300, Promoting the Anti-Apoptotic Phenotype of Senescent Cholangiocytes via Induced Transcription of the Pro-Survival Gene, BCL2L1

Presenter: Patrick L. Splinter, M.S.

Presentation Type: Oral Presentation
Presentation Date/Time: Sunday, November 10th at 5 p.m.

Location: Room 210, Hynes Convention Center

Financial Support: DK57993 and Chris M. Carlos and Catharine Nicole Jockisch Carlos Endowment Fund in Primary Sclerosing Cholangitis

 

Read the full abstracts from the PSC team here.

Join others discussing PSC